Mylan attacks Allergan over its Mohawk-allied patent strategy — but the CEO is sticking to his guns
Brent Saunders (center, with microphone) speaks at an Endpoints News event at the JP Morgan conference earlier this year
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
